Archive | Multaq RSS feed for this section

FDA warning on Multaq and Increased Risk of Death

22. December 2011


U.S. Food and Drug Administration has completed a safety review of Multaq (generic name dronedarone).  According to this review, in patients with permanent atrial fibrillation (AF),  Multaq increased the risk of serious cardiovascular events, including death. The  data was obtained from ATHENA and PALLAS clinical trials.  New information and recommendations are being provided by FDA for […]

Continue reading...